Early decisions can impact the success of a novel gene therapy, so how can therapeutics companies make sure to set off on the right track?
In this article, drug developers will learn some things that they should consider at the start of their therapeutic journey. We explore the impact of early technical decisions, including the importance of seeking high-yielding plasmids and a well-validated cell line. We cover logistical considerations, such as plasmid supply chain challenges and how to avoid them. Finally, we highlight the long-term benefits of forming a strategic partnership with a highly-experienced CDMO early in the therapeutic journey.
Fill out the form below to read the full article from WuXi Advanced Therapies.